Literature DB >> 22972475

Heart rate reduction in heart failure: ivabradine or beta blockers?

Maya Guglin1.   

Abstract

Ivabradine, a selective I f current inhibitor, decreasing the heart rate in those with sinus rhythm, has been added to the most recent European guidelines on heart failure. It is indicated in addition to beta blockers in patients with decreased left ventricular ejection fraction and sinus rate of over 70 beats per minute. Several well-designed studies including the BEAUTIFUL and the SHIFT trials demonstrated clear benefits of ivabradine in symptomatic patients, both with angina and with heart failure, with left ventricular systolic dysfunction. The main objective of this review is to provide a comprehensive summary of data on ivabradine, and to discuss the potential role of this new agent in the spectrum of modern therapeutics for heart failure.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 22972475     DOI： 10.1007/s10741-012-9347-6

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN： 1382-4147            Impact factor:   4.214


  76 in total

1.  Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.

Authors:  Sebastian Majewski; Sebastian Slomka; Ewa Zielinska-Wyderkiewicz; Maciej Ciebiada; Pawel Gorski
Journal:  Am J Cardiovasc Drugs       Date:  2012-06-01       Impact factor: 3.571

2.  Safety and effectiveness of ivabradine after cardiac transplantation.

Authors:  E Lage-Gallé; N Romero-Rodríguez; J Nevado-Portero; A Guisado-Rasco; M Sobrino-Márquez; M Gonzales-Vargas Machuca; M Fernández-Quero; A Campos-Pareja; S Ballesteros-Pradas; A Martínez-Martínez
Journal:  Transplant Proc       Date:  2010-10       Impact factor: 1.066

3.  Is target dose the treatment target? Uptitrating beta-blockers for heart failure in the elderly.

Authors:  Götz Gelbrich; Frank Edelmann; Simone Inkrot; Mitja Lainscak; Svetlana Apostolovic; Aleksandar N Neskovic; Finn Waagstein; Markus Loeffler; Stefan D Anker; Rainer Dietz; Hans-Dirk Düngen
Journal:  Int J Cardiol       Date:  2011-11-30       Impact factor: 4.164

4.  Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina.

Authors:  E Amosova; E Andrejev; I Zaderey; U Rudenko; C Ceconi; R Ferrari
Journal:  Cardiovasc Drugs Ther       Date:  2011-12       Impact factor: 3.727

5.  Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure.

Authors:  Hani N Sabbah; Ramesh C Gupta; Makoto Imai; Eric D Irwin; Sharad Rastogi; Martin A Rossing; Robert S Kieval
Journal:  Circ Heart Fail       Date:  2010-11-19       Impact factor: 8.790

6.  What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF).

Authors:  Lars Gullestad; John Wikstrand; Prakash Deedwania; Ake Hjalmarson; Kenneth Egstrup; Uri Elkayam; Stephen Gottlieb; Andrew Rashkow; Hans Wedel; Georgina Bermann; John Kjekshus
Journal:  J Am Coll Cardiol       Date:  2005-01-18       Impact factor: 24.094

7.  Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF.

Authors:  Paul J Hauptman; Peter J Schwartz; Michael R Gold; Martin Borggrefe; Dirk J Van Veldhuisen; Randall C Starling; Douglas L Mann
Journal:  Am Heart J       Date:  2012-06       Impact factor: 4.749

8.  Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling.

Authors:  Claudio Ceconi; Laura Comini; Silvia Suffredini; Francesca Stillitano; Muriel Bouly; Elisabetta Cerbai; Alessandro Mugelli; Roberto Ferrari
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-10-15       Impact factor: 4.733

Review 9.  Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.

Authors:  Dario DiFrancesco; John A Camm
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.

Authors:  Kim Fox; Ian Ford; Ph Gabriel Steg; Michal Tendera; Michele Robertson; Roberto Ferrari
Journal:  Eur Heart J       Date:  2009-08-31       Impact factor: 29.983
View more
  1 in total

Review 1.  How Heart Rate Should Be Controlled in Patients with Atherosclerosis and Heart Failure.

Authors:  Rose Mary Ferreira Lisboa da Silva; Anaisa Silva Roever Borges; Nilson Penha Silva; Elmiro Santos Resende; Gary Tse; Tong Liu; Leonardo Roever; Giuseppe Biondi-Zoccai
Journal:  Curr Atheroscler Rep       Date:  2018-09-17       Impact factor: 5.113
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.